Overview

A Study of DLX105-DMP in Subjects With Plaque Psoriasis

Status:
Not yet recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
A Pilot, Open-Label Study in Subjects with Mild-to-Moderate Plaque Psoriasis to Investigate the Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multidose Regimen of DLX105-DMP Administered to a Target Lesion
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
DelArrivo, Inc.
Treatments:
Unithiol